288 related articles for article (PubMed ID: 31746603)
1. Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
Lu Y; Gutgesell LM; Xiong R; Zhao J; Li Y; Rosales CI; Hollas M; Shen Z; Gordon-Blake J; Dye K; Wang Y; Lee S; Chen H; He D; Dubrovyskyii O; Zhao H; Huang F; Lasek AW; Tonetti DA; Thatcher GRJ
J Med Chem; 2019 Dec; 62(24):11301-11323. PubMed ID: 31746603
[TBL] [Abstract][Full Text] [Related]
2. Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
Tria GS; Abrams T; Baird J; Burks HE; Firestone B; Gaither LA; Hamann LG; He G; Kirby CA; Kim S; Lombardo F; Macchi KJ; McDonnell DP; Mishina Y; Norris JD; Nunez J; Springer C; Sun Y; Thomsen NM; Wang C; Wang J; Yu B; Tiong-Yip CL; Peukert S
J Med Chem; 2018 Apr; 61(7):2837-2864. PubMed ID: 29562737
[TBL] [Abstract][Full Text] [Related]
3. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
Lai A; Kahraman M; Govek S; Nagasawa J; Bonnefous C; Julien J; Douglas K; Sensintaffar J; Lu N; Lee KJ; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Moon MJ; Joseph JD; Darimont B; Brigham D; Grillot K; Heyman R; Rix PJ; Hager JH; Smith ND
J Med Chem; 2015 Jun; 58(12):4888-904. PubMed ID: 25879485
[TBL] [Abstract][Full Text] [Related]
4. Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.
Lu Y; Liu W
J Med Chem; 2020 Dec; 63(24):15094-15114. PubMed ID: 33138369
[TBL] [Abstract][Full Text] [Related]
5. GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models.
Guo S; Zhang C; Mottamal M; Hossain A; Liu J; Wang G
Breast Cancer Res Treat; 2020 Apr; 180(2):359-368. PubMed ID: 32030569
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
7. The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options.
Wang Y; Tang SC
Cancer Metastasis Rev; 2022 Dec; 41(4):975-990. PubMed ID: 36229710
[TBL] [Abstract][Full Text] [Related]
8. Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.
Xiong R; Zhao J; Gutgesell LM; Wang Y; Lee S; Karumudi B; Zhao H; Lu Y; Tonetti DA; Thatcher GR
J Med Chem; 2017 Feb; 60(4):1325-1342. PubMed ID: 28117994
[TBL] [Abstract][Full Text] [Related]
9. Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.
Keenan JC; Medford AJ; Dai CS; Wander SA; Spring LM; Bardia A
Expert Rev Anticancer Ther; 2024 Jun; 24(6):397-405. PubMed ID: 38642015
[TBL] [Abstract][Full Text] [Related]
10. Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.
Nagasawa J; Govek S; Kahraman M; Lai A; Bonnefous C; Douglas K; Sensintaffar J; Lu N; Lee K; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Joseph JD; Darimont B; Brigham D; Maheu K; Heyman R; Rix PJ; Hager JH; Smith ND
J Med Chem; 2018 Sep; 61(17):7917-7928. PubMed ID: 30086626
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader.
Wardell SE; Nelson ER; Chao CA; Alley HM; McDonnell DP
Endocr Relat Cancer; 2015 Oct; 22(5):713-24. PubMed ID: 26162914
[TBL] [Abstract][Full Text] [Related]
12. Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status.
Downton T; Zhou F; Segara D; Jeselsohn R; Lim E
Drug Des Devel Ther; 2022; 16():2933-2948. PubMed ID: 36081610
[TBL] [Abstract][Full Text] [Related]
13. Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD).
Liu J; Zheng S; Akerstrom VL; Yuan C; Ma Y; Zhong Q; Zhang C; Zhang Q; Guo S; Ma P; Skripnikova EV; Bratton MR; Pannuti A; Miele L; Wiese TE; Wang G
J Med Chem; 2016 Sep; 59(17):8134-40. PubMed ID: 27529700
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3
El-Ahmad Y; Tabart M; Halley F; Certal V; Thompson F; Filoche-Rommé B; Gruss-Leleu F; Muller C; Brollo M; Fabien L; Loyau V; Bertin L; Richepin P; Pilorge F; Desmazeau P; Girardet C; Beccari S; Louboutin A; Lebourg G; Le-Roux J; Terrier C; Vallée F; Steier V; Mathieu M; Rak A; Abecassis PY; Vicat P; Benard T; Bouaboula M; Sun F; Shomali M; Hebert A; Levit M; Cheng H; Courjaud A; Ginesty C; Perrault C; Garcia-Echeverria C; McCort G; Schio L
J Med Chem; 2020 Jan; 63(2):512-528. PubMed ID: 31721572
[TBL] [Abstract][Full Text] [Related]
15. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD
Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
[TBL] [Abstract][Full Text] [Related]
17. The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs).
Wang L; Sharma A
ChemMedChem; 2020 Nov; 15(22):2072-2097. PubMed ID: 32916035
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel 2H-chromene-3-carbonyl derivatives as selective estrogen receptor degraders (SERDs): Design, synthesis and biological evaluation.
Lu X; Teng Y; Lin X; Xiao M; Liu C; Chi X; Zhang Y; Luo G; Xiang H
Bioorg Chem; 2021 Apr; 109():104714. PubMed ID: 33618254
[TBL] [Abstract][Full Text] [Related]
19. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
20. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.
Márquez-Garbán DC; Deng G; Comin-Anduix B; Garcia AJ; Xing Y; Chen HW; Cheung-Lau G; Hamilton N; Jung ME; Pietras RJ
J Steroid Biochem Mol Biol; 2019 Oct; 193():105415. PubMed ID: 31226312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
